Trained Market Monkey

Maurice was discovered mid-tantrum, hurling banana peels at his monitor while muttering about market psychology and FDA approval paradoxes.

Here’s a question that keeps me awake at night, swinging from one side of my cage to the other: Why does the stock market sometimes punish good news like it just discovered a rotten banana in the bunch?

Take Rocket Pharmaceuticals (RCKT), a late-stage biotech company that just scored what should be a champagne-popping, corner-office-dancing moment. In late March 2026, the FDA granted accelerated approval for KRESLADI, their gene therapy for severe Leukocyte Adhesion Deficiency-I (LAD-I)—a rare genetic disorder that basically breaks a child’s immune system. This is the kind of win that biotech dreams are made of. This is the moment investors theoretically wait for.

And the stock went down 8.9%.

Welcome to biotech investing, where up is sometimes down and the only thing more unpredictable than a monkey’s breakfast habits is Wall Street’s emotional thermostat.

The Approval That Split the Room

Let me back up and explain what Rocket actually does, because understanding this company requires understanding the difference between “approved” and “approved the way we hoped.”

Rocket is essentially betting its entire future on gene therapy—the idea that you can deliver a healthy gene to cells and fix genetic diseases at their source. Think of it like this: most pharmaceutical companies are selling band-aids. Rocket is trying to perform surgery on the DNA itself. It’s more ambitious, more risky, and if it works, potentially more transformative.

Their pipeline includes some genuinely interesting candidates: programs for Danon disease (a cardiac disorder that kills early), Fanconi anemia (a blood disorder), and several cardiac conditions. But KRESLADI—their first FDA approval—is for LAD-I, a condition that affects maybe a few hundred kids globally. Beautiful science. Tiny market.

The approval itself is real. It’s accelerated approval, which means the FDA essentially said, “We believe this works based on early data, and we’re not making patients wait.” That’s significant. That’s the kind of validation that launches biotech companies into the stratosphere.

So why did investors throw bananas at this news?

Because accelerated approval comes with strings. The company will need to run additional confirmatory trials. The market size for LAD-I treatment is… let’s be honest… modest. And in biotech, one approval doesn’t mean the rest of the pipeline suddenly becomes gold. It means one thing worked. The other five things in your backpack? Still unknown.

The Real Story: What’s Actually Coming

Here’s where my tail stops twitching and starts to perk up: Foxy’s thesis isn’t really about KRESLADI. KRESLADI is a proof-of-concept. It’s the appetizer, not the main course.

The real catalysts are coming in 2026-2027, and they’re in Rocket’s cardiac gene therapy programs. Danon disease (RP-A501) is in Phase 2. Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) is in Phase 1. These are the shots at the big stage. Cardiac disorders affect millions of people. If even one of these works in a meaningful way, we’re talking about a fundamentally different company valuation.

The market cap is currently around $395 million. At $3.64 per share, this is a penny-stock-adjacent biotech that’s been beaten down hard. The 52-week high was $8.26. That’s not ancient history—that’s where the market thought this company could go when sentiment was better.

Let me throw some numbers at you. Rocket has an eye-watering debt-to-equity ratio of 8.97. That’s… a lot. But here’s the thing: for biotech companies that are genuinely late-stage (meaning they have products potentially heading to approval), high leverage isn’t quite as terrifying as it sounds. Why? Because if the product works, the cash injection from commercial sales rewrites everything. If it doesn’t work, leverage doesn’t matter anyway because you’re bankrupt.

Free cash flow is negative $104 million annually, which tells you exactly what you need to know: Rocket isn’t making money. They’re burning it on research and development. That’s what pre-commercial biotech does. The clock is ticking, but it’s not doomsday—not yet.

The Monkey Momentum Thesis

Foxy flagged this as a medium-risk, confidence-8 buy at $3.55, targeting $8.50. We’re basically at entry right now (trading at $3.64). Let me explain why this makes sense, and why it also makes me slightly nervous.

The Bull Case: Rocket has legitimate science. KRESLADI approval proves the platform works. The pipeline has shots in a market (cardiac genetic disorders) that’s worth billions if you can actually cure people. Gene therapy is being taken seriously by the FDA and the medical community in a way it wasn’t five years ago. The beta of 0.574 means this stock doesn’t move in lockstep with the market—it marches to its own drummer. For risk-adjusted returns, that’s valuable. If the Danon disease program shows promise in 2026, this stock could easily double or triple. The institutional interest is there (Wedbush called it “significantly undervalued”). At roughly 4x market cap to current price, it’s priced for moderate skepticism, not catastrophic failure.

The Bear Case: Gene therapy is still relatively unproven at scale. Phase 2 and Phase 1 data can disappoint. The short ratio is 4.64%, suggesting bears are circling. The debt situation is real—if they need another capital raise before a major approval, shareholders get diluted. LAD-I approval didn’t move the needle much because the market size is small. Why should Danon disease or PKP2-ACM be different? Clinical trial failures happen. They happen a lot. And if Rocket runs out of cash before seeing Phase 3 approvals, this becomes a zero.

The Three-Year Narrative

Let me paint the scenario I’m imagining. If I’m right—and I’m frequently not, so bear that in mind—here’s how this unfolds:

2026-2027: Phase 2 data for Danon disease comes out. It’s promising (this is where I’m daydreaming a little). Maybe not a home run, but enough to make the street think, “Oh, maybe this actually works.” The stock moves to $5-6 range on that momentum.

2027-2028: Phase 3 initiation for the promising programs. Regulatory feedback is positive. More data readouts. The narrative shifts from “interesting science” to “potential commercial candidate.” Stock drifts toward $7-8.

2028+: If we get approvals or strong Phase 3 interim data, we’re looking at a completely different valuation. The company moves from “small biotech with potential” to “emerging gene therapy commercial player.” That’s where the $8.50+ target makes sense. That’s where early investors who bought at $3.50 are sitting on 2.4x returns before considering compounding or further upside.

But here’s the honest part: this is a binary-outcome bet. Gene therapy either works or it doesn’t. Clinical trials either succeed or they fail. There’s no middle ground of “kind of profitable.” This is a five-year story compressed into clinical milestones. Your timeline needs to match that. If you need money in two years, this isn’t your stock. If you can afford to wait and you believe in the science, then you’re essentially saying: “I think there’s more than a 50% chance that Rocket’s gene therapy programs work. And if they do, this company is worth 2-3x more than it is today.”

Why the FDA Approval Tanked the Stock (And Why That Might Be Beautiful)

Remember that 8.9% drop after KRESLADI approval? That’s not a bug in this thesis—it’s a feature. Here’s why:

The market was pricing in accelerated approval for LAD-I. It was already baked in. The actual approval removed uncertainty but confirmed that LAD-I alone isn’t going to be a blockbuster. Smart money acknowledged this and rotated out. Weak hands panicked. The stock was left with people who either (a) didn’t own it and should buy it cheaper, or (b) actually believed in the longer-term pipeline enough to hold through a temporary disappointment.

That’s actually the ideal setup for a patient investor. The enthusiasm has been wrung out. The realistic expectations have been set. Now you can buy while the crowd is still thinking about why they sold instead of why they should have held.

The Risk I’m Not Ignoring

The short ratio suggests this is already a shorted stock. That can mean either (a) bears know something we don’t, or (b) people are shorting a speculative biotech because that’s what you do with speculative biotech. But it’s worth watching. If Rocket hits a serious clinical snag, shorts will amplify the decline. Biotech can get ugly fast.

The cash burn is real. At negative $104 million in free cash flow, they’re consuming runway. They’ll need to either get financing or demonstrate enough progress to deserve financing. That’s not a secret—it’s just the biotech lifecycle.

And let’s be clear: most biotech programs fail. Gene therapy is new enough that we don’t have decades of data on long-term success rates. You’re investing in a team’s ability to execute on science that still has unknowns.

My Actual Opinion (Which Is Worth Exactly What You Paid For It)

I’m bullish on Rocket, but cautiously so. Not in the way you’d be bullish on Apple or Microsoft. More like the way you’d be enthusiastic about a talented poker player—good odds, but variance is still a factor.

The entry price is reasonable. $3.55-$3.65 is a fair entry for someone who believes gene therapy is real and Rocket’s science is legitimate. The target of $8.50 assumes success in clinical trials and regulatory approvals over the next 2-3 years. That’s not crazy. That’s not a 10-bagger fantasy. That’s a “multiple shots on goal” scenario.

If I had to bet on one thing, I’d bet that Danon disease data in 2026-2027 will be the inflection point. That’s the program that, if it works, makes Rocket a real company with a real product in a real market. LAD-I is proof. Danon is the opportunity.

For the right investor—someone with 3-5 year time horizon, moderate risk tolerance, and enough portfolio cushion to take a meaningful loss without panic—this is worth a position. Not an oversized position. Not your entire portfolio. But a position worth monitoring and defending through the inevitable volatility.

Maurice rates this a 7.5 out of 10 on the Monkey Momentum Index. It’s above-average opportunity with medium-to-high execution risk. It’s the kind of stock that will either be a brilliant buy or a “why did I ever believe in gene therapy?” lesson. Given that we’re closer to clinical proof points than we’ve ever been, I’m more excited than worried. But only slightly.

Now if you’ll excuse me, I have some bananas to peel and a research report on cardiac biology to pretend to understand.